Carotid Stenting and Mechanical Thrombectomy in Patients with Acute Ischemic Stroke and Tandem Occlusions: Antithrombotic Treatment and Functional Outcome

V. Da Ros, J. Scaggiante, F. Sallustio, S. Lattanzi, M. Bandettini, A. Sgreccia, C. Rolla-Bigliani, E. Lafe, G. Sanfilippo, M. Diomedi, M. Ruggiero, N. Haznedari, M. Giannoni, C. Finocchi and R. Floris

*AJNR Am J Neuroradiol* 2020, 41 (11) 2088-2093
doi: [https://doi.org/10.3174/ajnr.A6768](https://doi.org/10.3174/ajnr.A6768)
http://www.ajnr.org/content/41/11/2088
Carotid Stenting and Mechanical Thrombectomy in Patients with Acute Ischemic Stroke and Tandem Occlusions: Antithrombotic Treatment and Functional Outcome

V. Da Ros, J. Scaggiante, F. Sallustio, S. Lattanzi, M. Bandettini, A. Sgreccia, C. Rolla-Bigliani, E. Lafe, G. Sanfilippo, M. Diomedi, M. Ruggiero, N. Haznedari, M. Giannoni, C. Finocchi, and R. Floris

ABSTRACT

BACKGROUND AND PURPOSE: There is no consensus on the optimal antithrombotic medication for patients with acute ischemic stroke with anterior circulation tandem occlusions treated with emergent carotid stent placement and mechanical thrombectomy. The identification of factors influencing hemorrhagic risks can assist in creating appropriate therapeutic algorithms for such patients. This study aimed to investigate the impact of medical therapy on functional and safety outcomes in patients treated with carotid stent placement and mechanical thrombectomy for tandem occlusions.

MATERIALS AND METHODS: A multicenter retrospective study on prospectively collected data was conducted. Only patients treated with carotid stent placement and mechanical thrombectomy for tandem occlusions of the anterior circulation were included. Univariate and multivariate analyses were performed on preprocedural, procedural, and postprocedural variables to assess factors influencing clinical outcome, symptomatic intracranial hemorrhage, stent patency, and successful intracranial vessel recanalization.

RESULTS: Ninety-five patients with acute ischemic stroke and tandem occlusions were included. Good clinical outcome (mRS ≤ 2) at 3 months was reached by 33 (39.3%) patients and was associated with baseline ASPECTS ≥ 8 (OR = 1.53; 95% CI, 1.16–2.00), ≤ 2 mechanical thrombectomy attempts (OR = 0.71; 95% CI, 0.55–0.99), and the absence of symptomatic intracranial hemorrhage (OR = 0.13; 95% CI, 0.03–0.51). Symptomatic intracranial hemorrhage was associated with a higher amount of intraprocedural heparin, ASPECTS ≤ 7, and ≥ 3 mechanical thrombectomy attempts. No relationships among types of acute antiplatelet regimen, intravenous thrombolysis, and symptomatic intracranial hemorrhage were observed. Patients receiving dual-antiplatelet therapy after hemorrhagic transformation had been ruled out on 24-hour CT were more likely to achieve functional independence and had a lower risk of symptomatic intracranial hemorrhage.

CONCLUSIONS: During carotid stent placement and mechanical thrombectomy for tandem occlusion treatment, higher intraprocedural heparin dosage (≥3000 IU) increased symptomatic intracranial hemorrhage risk when the initial ASPECTS was ≤7, and mechanical thrombectomy needs more than one passage for complete recanalization. Antiplatelets antiplatelets use were safe, and dual-antiaggregation therapy was related to better functional outcomes.

ABBREVIATIONS: AIS = acute ischemic stroke; ICH = intracranial hemorrhage; MT = mechanical thrombectomy; sICH = symptomatic intracranial hemorrhage; TO = tandem occlusion

Received April 21, 2020; accepted after revision July 7.

From the Department of Biomedicine and Prevention (V.D.R., J.S., R.F.), Interventional Neuroradiology Unit, and Comprehensive Stroke Center (F.S., M.D.), Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy; Neurological Clinic (S.L.), Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy; Neurological Clinic (M.B., C.F.), Department of Neurosciences and Interventional Neuroradiology Unit (A.S., E.L., G.S.), IRCCS Policlinico San Matteo, Pavia, Italy; Department of Diagnostic and Interventional Neuroradiology (C.R.–B.), Policlinico Universitario, San Martino, Italy; Neuroradiology Unit (M.R., N.H.), AUSL Romagna, Cesena, Italy; and Neuroradiological Clinic (M.G.), Department of Radiological Sciences, AOUMospedali Riuniti, Ancona, Italy.

V.D. Ros and J. Scaggiante contributed equally to the article.

Carotid stenting (complete occlusion or ≥90% stenosis according to the NASCET criteria) and ipsilateral occlusion of proximal intracranial large vessels (ICA, the M1 and/or M2 segment of the middle cerebral artery).2

Acute ischemic stroke (AIS) caused by TOs is generally associated with a poor prognosis when left untreated.3

Please address correspondence to Valerio Da Ros, MD, Department of Biomedicine, Interventional Neuroradiology unit, University of Rome Tor Vergata, Viale Oxford 81, Rome, Italy; e-mail: darosvalerio@gmail.com

Indicates article with supplemental on-line tables.

http://dx.doi.org/10.3174/ajnr.A6768

2088  Da Ros  Nov 2020  www.ajnr.org
Although intravenous thrombolysis with tPA remains part of the criterion standard treatment, tandem occlusions respond poorly to intravenous thrombolysis alone, likely due to the poor responsiveness of large thrombi to enzymatic digestion. Because intracranial vessel recanalization is the most powerful predictor of favorable clinical outcome, endovascular therapy is the standard of care for tandem occlusions. However, the most appropriate interventional strategy to manage the extracranial carotid disease remains controversial.

Systematic reviews and post hoc analyses reported similar clinical outcomes at 3-month follow-up in patients with acute ischemic stroke and tandem occlusions treated with carotid stent placement or angioplasty. Conversely, a recent meta-analysis, a prospective nonrandomized trial, and the international multicenter Thrombectomy in TANdem Occlusion (TITAN) and Systematic Evaluation of Patients Treated with Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry suggested better outcomes and higher recanalization rates for patients undergoing carotid stent placement.

The best antiplatlet/anticoagulant management to reduce the risk of postinterventional symptomatic intracranial hemorrhage (sICH) and prevent stent re-occlusion in these patients remains a matter of ongoing debate. Because emergent carotid stent placement during acute ischemic stroke requires antithrombotic agents, this strategy may be less appealing due to the intracranial hemorrhage (ICH) risk, especially for patients already receiving intravenous thrombolysis. Moreover, as addressed by the TITAN investigators, the use of intraprocedural heparin in tandem occlusions failed to demonstrate better functional, angiographic, or safety outcomes. So far, little evidence exists to guide the medical therapy of tandem occlusions treated with carotid stent placement, and high-quality analyses and randomized controlled trials are needed.

This study aimed to investigate the impact of medical therapy on functional and safety outcomes in patients treated with carotid stent placement and mechanical thrombectomy for tandem occlusions.

**MATERIALS AND METHODS**

**Study Design**

We retrospectively evaluated all consecutive patients admitted with acute ischemic stroke between January 2018 and December 2019 in 5 Italian neurointerventional centers.

We included in this study only patients treated with emergent carotid stent placement and mechanical thrombectomy for a tandem occlusion, defined as an extracranial ICA lesion (complete occlusion or \( \geq 90\% \) stenosis according to the NASCET criteria) and an ipsilateral proximal intracranial large-vessel occlusion (intracranial ICA, the M1 and/or M2 segment of the middle cerebral artery) confirmed at initial cerebral angiography. Eligibility for intravenous thrombolysis and endovascular treatment was evaluated at each center according to the American Heart Association/American Stroke Association guidelines.

Preprocedural, procedural, 24- to 48-hour postprocedural, discharge, and 3-month data were prospectively collected. No ethics committee approval was required for this retrospective observational study.

We evaluated the following variables: demographic characteristics (ie, age, sex), cardiovascular risk factors (ie, atrial fibrillation, arterial hypertension, diabetes mellitus, hypercholesterolemia, smoking, previous cardio-cerebrovascular accidents), clinical and radiologic assessments (ie, mRS, NIHSS score, imaging characteristics [ie, ASPECTS]), stroke etiology according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, stroke side, hemorrhagic transformation, stent patency, procedural time, (ie, onset-to-groin time, onset-to-recanalization time), number of mechanical thrombectomy (MT) attempts, type of stent (single- or dual-layer), and medical therapy (ie, preprocedural medications, intra- and postprocedural anticoagulant/antiplatelet protocols).

Good clinical outcome was defined as mRS 0–2 at 3-month follow-up, and favorable clinical outcome, as mRS 0–3.

**Imaging Evaluation**

All CT scans were obtained with 64 slices using a helicoid acquisition (GE LightSpeed VCT 64; GE Healthcare). At each institution, 2 neurointerventional radiologists independently analyzed preprocedural CT scans. Any disagreement was resolved by consensus with a third neuroradiologist (ie, head of the department). The cervical ICA occlusion was included in the TOAST classification on DSA, according to clinical and angiographic imaging characteristics. Successful recanalization was defined as modified TICI 2b–3 on DSA.

CT angiography was used to assess stent patency within 72 hours from treatment. Acute in-stent occlusion was defined as occlusion of the carotid stent within 72 hours after stent placement.

Symptomatic intracranial hemorrhage (sICH) was defined as parenchymal hematoma type 1 or 2 using the European Cooperative Acute Stroke Study (ECASS) III grading, according to imaging at 24 hours, associated with an increase of at least 4 NIHSS points within 24 hours, or resulting in death.

**Emergent Carotid Stent Placement and MT**

There were no technical restrictions to perform cervical ICA stent placement and intracerebral mechanical thrombectomy. Each center independently decided the stent type (ie, single-layer stent or dual-layer stent) and the mechanical thrombectomy technique (ie, aspiration and/or stent retriever) according to their experience.

**Anticoagulation/Antiaggregation**

For each patient, we assessed preprocedural, intraprocedural, and postprocedural medications, independently decided at each institution.

IV heparin sodium use was administered at the discretion of each center. The total amount of IV heparin was calculated on the basis of the speed of infusion, use of a bolus, and time from first infusion to the end of the procedure.

In patients already receiving antiplatelet medications, a single-antiplatelet therapy was defined as a regular dosage of aspirin (Bayer) (ie, up to 300 mg) or clopidogrel 75 mg. In patients without antiplatelet medication, a dose of 500 mg of intravenous lysine acetylsalicylate administered before deployment of carotid stent placement was considered a regular single dosage. Dual-antiplatelet therapy was defined as a treatment with combined
medications (eg, aspirin with clopidogrel) or a double regular dose of a single drug (eg, lysine acetylsalicylate, 1000 mg).

**Statistical Analysis**

Continuous variables were reported as mean ± SD or median with range, and categoric variables, as number and percentage. Contingency analyses for categoric variables were performed using the exact $\chi^2$ test.

Group comparisons were performed with the ANOVA and univariate logistic regression analyses to identify factors influencing clinical outcomes, stent patency, successful revascularization, and sICH. A 2-sided $P$ value < .05 indicated statistical significance. The multivariate analysis was performed using a general linear regression model (MANOVA), with a stepwise backward elimination procedure; a separate ANOVA was conducted for each dependent variable at an $\alpha$ level of .025. Analyses were performed using SPSS, Version 23.0 (IBM).

**RESULTS**

**Study Population**

Between January 2018 and December 2019, one thousand eighty patients admitted with acute ischemic stroke underwent mechanical thrombectomy; 214 patients (19.8%) presented with extracranial/intracranial tandem occlusions, of whom 95 patients (44.4%) received emergent carotid stent placement (flow chart in the Figure). The characteristics of the study population are presented in Table 1.

Fifty-six patients (58.9%) presented with a left-hemispheric stroke. Median baseline ASPECTS was 8, and the NIHSS score was 16.8. Forty-five patients (47.4%) were treated with mechanical thrombectomy plus intravenous thrombolysis. The mean onset-to-groin time was 284.5 ± 156.4 minutes, the mean onset-to-recanalization time was 376.7 ± 168.3 minutes, and the mean procedural time was 90.6 ± 58.2 minutes.

**Clinical and Angiographic Outcomes**

A successful intracranial recanalization (modified TICI 2b–3) was achieved in 58 of 95 patients (61.1%): TICI 3 in 31 (32.6%), TICI 2c in 5 (5.3%), and TICI 2b in 22 (23.2%). The rate of unsuccessful recanalization was 38.9%: TICI 2a in 28 patients (29.5%), TICI 1 in 3 (3.2%), and TICI 0 in 6.3%.

The rate of postprocedural sICH was 27.7%. Parenchymal hematoma type 1 occurred in 12 (12.7%) patients, and parenchymal hematoma type 2, in 14 (14.9%) patients. Clinical follow-up at 3 months from stroke was available in 84 patients: Thirty-three (39.3%) were functionally independent (mRS 0–2), and 47 (56%) achieved a favorable outcome (mRS 0–3).

**Management of Tandem Lesions**

Emergent carotid artery stent placement was performed in all patients. In 87 patients, a single-layer carotid stent was used, and 8 patients were treated with a dual-layer carotid stent.

**Factors Influencing Clinical Outcomes: ANOVA, Univariate, and Multivariate Analyses**

The subgroup comparison of patients with functional independence (mRS 0–2) and dependence at 3-month follow-up is presented in On-line Table 1. Patients with good clinical outcome were younger (mean age, 61.4 versus 65.9 years), presented with shorter onset-to-recanalization time (median, 317.5 versus 376.7 minutes), and were younger (mean age, 61.4 versus 65.9 years), presented with shorter onset-to-recanalization time (median, 317.5 versus 376.7 minutes).
360 minutes), had a higher rate of successful intracerebral recanalization (modified TICI ≥ 2b: 75.8% versus 52.9%), were more commonly prescribed postprocedural dual-antiplatelet therapy (67.9% versus 25.9%), and showed lower rates of sICH (9.1% versus 42%). All other cofactors were not statistically different between groups. The univariate logistic regression analysis is presented in On-line Table 2.

Factors associated with a good clinical outcome were higher baseline ASPECTS (OR = 1.53; 95% CI, 1.16–2; P = .002), lower rates of sICH (OR = 0.13; 95% CI, 0.37–0.51; P = .001), and ≤2 MT attempts (OR = 0.71; 95% CI, 0.55–0.99; P = .04). Moreover, those patients receiving dual-antiplatelet therapy after hemorrhagic transformation had been ruled out on 24-hour CT had higher chances of functional independence at 3-month follow-up (OR = 6.03; 95% CI, 1.87–19.44; P = .003).

All other intraprocedural or postprocedural anticoagulant/antiplatelet protocols were not associated with good clinical outcome.

The multivariate general linear analysis (MANOVA) reported a relevant difference between patients with and without good clinical outcome when considered jointly on the variables of baseline ASPECTS, sICH, postprocedural dual-antiplatelet therapy, and number of MT attempts.

There was a significant difference between patients with and without good clinical outcome on baseline ASPECTS, F (1–53) = 8.57, P = .001, partial η² = 0.14, with functionally independent patients having higher mean ASPECTS on baseline CT (8.4 ± 0.4; 95% CI, 7.9–9.2) versus dependent patients (6.9 ± 0.4; 95% CI, 6.7–7.7).

The multivariate analysis confirmed the association with sICH (negative correlation; P = .005) and postprocedural dual-antiplatelet therapy (positive correlation; P = .003). Moreover, mean mechanical thrombectomy attempts of 1.9 ± 0.3 (95% CI, 1.3–2.5; P = .004) were associated with good clinical outcome versus dependent patients undergoing 3.2 ± 0.3 (95% CI, 2.6–3.9) attempts to recanalize the intracerebral occlusion.

**Factors Influencing Symptomatic Intracerebral Hemorrhage: ANOVA, Univariate, and Multivariate Analyses**

The subgroup comparison of patients with and without sICH is presented in On-line Table 1. The only factor associated with sICH was a lower baseline ASPECTS (median, 6.5 versus 8) confirmed by univariate logistic regression analysis (On-line Table 2; P = .009).

Moreover, those patients receiving dual-antiplatelet therapy after hemorrhagic transformation had been ruled out on 24-hour CT had less chance of sICH (OR = 2.4; 95% CI, 1–5.8; P = .02).

The multivariate general linear analysis (MANOVA) reported a significant difference between patients with and without symptomatic ICH when considered jointly on the variables baseline ASPECTS, intraprocedural heparin, and number of mechanical thrombectomy attempts, the Wilk Λ = 0.8, F (3.80) = 6.03, P = .001, partial η² = 0.18.

There was a significant difference between patients with and without sICH in intraprocedural heparin administration, F (1–84) = 6.4, P = .01, partial η² = 0.07, with patients with sICH having lower ASPECTS on baseline CT (mean = 6.6 ± 0.4; 95% CI, 5.8–7.4) compared with patients without sICH (8.3 ± 0.2; 95% CI, 7.8–8.7).

There was a significant difference between patients with and without sICH in the number of mechanical thrombectomy attempts, F (1–84) = 32.14, P = .002, partial η² = 0.1, with sICH in patients treated with a higher number of passes (mean, 3.3 ± 0.3; 95% CI, 2.6–4.1) compared with those without sICH (1.9 ± 0.2; 95% CI, 1.5–2.4).

**DISCUSSION**

In this study, we assessed functional outcome and complications in patients with acute ischemic stroke and tandem occlusions treated with emergent carotid stent placement and mechanical thrombectomy. We focused our multicenter retrospective analysis on this specific subgroup of patients with special regard for medical management to respond to the demanding questions raised after the recently reported higher successful recanalization rates and better clinical outcome in tandem occlusions managed with carotid stent placement.13–16

We found that a large ischemic core at the initial CT scan (ASPECTS ≤ 7), >2 mechanical thrombectomy attempts, and ≥3000 IU of intraprocedural heparin were significant predictors of sICH (Table 2). Functional independence was related to a small ischemic core (ASPECTS ≥ 8) and with the first-passages effect (ie, successful recanalization obtained with ≤2 mechanical thrombectomy attempts) (Table 2). Moreover, both single- and dual-antiplatelet therapy seem safe in emergent carotid stent placement, even if patients receive intravenous thrombolysis. Despite these results differing from those reported by van de Graaf et al,20 they are in accordance with the most recent data from the TITAN registry.29
Furthermore, patients receiving dual-antiplatelet therapy after ICH had been ruled out on postprocedural CT had higher chances of functional independence at 3 months from stroke, confirming the safety profile of antiplatelet therapy. This finding is in line with the study by Zhu et al.,

Conclusions

In the literature, there are few data to guide management of tandem occlusions in patients with acute ischemic stroke, and optimal antithrombotic therapy remains to be assessed for patients treated with emergent carotid artery stent placement. In our analysis, regular doses of intraprocedural heparin (≥3000 IU) were associated with sICH, antiplatelets were safe, and dual-antiaggregation therapy was related to better functional outcomes. The current findings may inform clinical practice and provide support for a prospective randomized controlled trial aimed at assessing endovascular treatment of patients with tandem occlusions.

**REFERENCES**

1. Ferguson Gary G, Eliasziw M, Barr Hugh WK, et al. The North American Symptomatic Carotid Endarterectomy Trial. Stroke 1999;30:1751–58 CrossRef Medline

2. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019–30 CrossRef Medline

3. Rubiera M, Ribo M, Delgado-Mederos R, et al. Tandem internal carotid artery/middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis. Stroke 2006;37:2301–05 CrossRef Medline

4. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke—A Guide for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2019;50:e344–418 CrossRef Medline

5. Kim YS, Garami Z, Mikulik R, et al. Early recanalization rates and clinical outcomes in patients with tandem internal carotid artery/middle cerebral artery occlusion and isolated middle cerebral artery occlusion. Stroke 2005;36:869–71 CrossRef Medline

6. Goyal M, Menon BK, van Zwan WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016;387:1723–31 CrossRef Medline

7. Bracard S, Ducrocq X, Mas JL, et al; THRACtive Investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRAcE): a randomised controlled trial. Lancet Neurol 2016;15:1138–47 CrossRef Medline

8. Berkhemer OA, Fransen PS, Beumer D, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11–20 CrossRef Medline

9. Campbell BC, Mitchell PJ, Kleining TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009–18 CrossRef Medline

10. Jovin TG, Chamorro A, Cobo E, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296–2306 CrossRef Medline

**Table 2: Multivariate analysis of factors influencing symptomatic ICH and functional independence**

| Factors                                      | Mean   | 95% CI     | P Value |
|----------------------------------------------|--------|------------|---------|
| Influencing symptomatic ICH                  |        |            |         |
| Intraprocedural heparin ≥3000 IU             | 3547 ± 588 IU | 2277–4718 | .01     |
| ASPECTS ≤7                                   | 6.6 ± 0.4 | 5.8–7.4   | .001    |
| MT attempts ≥3                               | 3.3 ± 0.3 | 2.6–4.1   | .002    |
| Influencing functional independence (mRS ≤2) | 8.4 ± 0.4 | 7.9–9.2   | .001    |
| ASPECTS ≥8                                   | 1.9 ± 0.3 | 1.3–2.5   | .004    |

In the literature, there are few data to guide management of tandem occlusions in patients with acute ischemic stroke, and optimal antithrombotic therapy remains to be assessed for patients treated with emergent carotid artery stent placement. In our analysis, regular doses of intraprocedural heparin (≥3000 IU) were associated with sICH, antiplatelets were safe, and dual-antiaggregation therapy was related to better functional outcomes. The current findings may inform clinical practice and provide support for a prospective randomized controlled trial aimed at assessing endovascular treatment of patients with tandem occlusions.
11. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372:2285–95 CrossRef Medline

12. Wilson MP, Murad MH, Kring, T, et al. Management of tandem occlusions in acute ischemic stroke - intracranial versus extracranial first and extracranial stenting versus angioplasty alone: a systematic review and meta-analysis. J Neurointerv Surg 2018;10:721–28 CrossRef Medline

13. Assis Z, Menon BK, Goyal M, et al. Acute ischemic stroke with tandem lesions: technical endovascular management and clinical outcomes from the ESCAPE trial. J Neurointerv Surg 2018;10:429–33 CrossRef Medline

14. Sadeh-Gonik U, Tau N, Friedmann T, et al. Thrombectomy outcomes for acute stroke patients with anterior circulation tandem lesions: a clinical registry and an update of a systematic review with meta-analysis. Eur J Neurol 2018;25:693–700 CrossRef Medline

15. Li W, Chen Z, Dai Z, et al. Management of acute tandem occlusions: stent-retriever thrombectomy with emergency stenting or angioplasty. J Int Med Res 2018;46:2578–86 CrossRef Medline

16. Zhu F, Bracard S, Anxionnat R, et al. Impact of emergent cervical carotid stenting in tandem occlusion strokes treated by thrombectomy: a review of the TITAN collaboration. Front Neurol 2019;10:206 CrossRef Medline

17. Jadhav AP, Zaidat OO, Liebeskind DS, et al. Emergent management of tandem lesions in acute ischemic stroke. Stroke 2019;50:428–33 CrossRef Medline

18. Papanagiotou P, Haussen DC, Turjman F, et al; TITAN Investigators. Carotid stenting with antithrombotic agents and intracranial thrombectomy leads to the highest recanalization rate in patients with acute stroke with tandem lesions. JACC Cardiovasc Interv 2018;11:1290–99 CrossRef Medline

19. Jacquin G, Poppe AY, Labrie M, et al. Lack of consensus among stroke experts on the optimal management of patients with acute tandem occlusion. Stroke 2019;50:1254–56 CrossRef Medline

20. van de Graaf RA, Chalos V, Del Zoppo GJ, et al. Periprocedural antithrombotic treatment during acute mechanical thrombectomy for ischemic stroke: a systematic review. Front Neurol 2018;9:238 CrossRef Medline

21. Blassiau A, Gawlitza M, Manceau PF, et al. Mechanical thrombectomy for tandem occlusions of the internal carotid artery: results of a conservative approach for the extracranial lesion. Front Neurol 2018;9:928 CrossRef Medline

22. Thrombectomy in TANdem Occlusion. NCT03978988. 2020. clinicaltrials.gov. Accessed April 4, 2020

23. Wilson JT, Hareendran A, Grant M, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002;33:2243–46 CrossRef Medline

24. Lyden P. Using the National Institutes of Health Stroke Scale: a cautionary tale. Stroke 2017;48:513–19 CrossRef Medline

25. Pexman JH, Barber PA, Hill MD, et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol 2001;22:1534–42 Medline

26. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial—TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41 CrossRef Medline

27. Zaidat OO, Yoo AJ, Khatri P, et al; STIR Thrombolysis in Cerebral Infarction (TICI) Task Force. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 2013;44:2650–63 CrossRef Medline

28. Hacke W, Kaste M, Bluhmki E, et al. Thrombolyis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–29 CrossRef Medline

29. Zhu F, Anadani M, Labreuche J, et al; TITAN Investigators. Impact of antiplatelet therapy during endovascular therapy for tandem occlusions: a collaborative pooled analysis. Stroke 2020;51:1522–29 CrossRef Medline

30. von Kummer R, Broderick JP, Campbell BC, et al. The Heidelberg Bleeding Classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke 2015;46:2981–86 CrossRef Medline

31. Nahab F, Walker GA, Dion JE, et al. Safety of periprocedural heparin in acute ischemic stroke endovascular therapy: the multi MERCI trial. J Stroke Cerebrovasc Dis 2012;21:790–93 CrossRef Medline

32. Gory B, Haussen DC, Piotin M; et al; TITAN investigators. Impact of intravenous thrombolysis and emergent carotid stenting on reperfusion and clinical outcomes in patients with acute stroke with tandem lesion treated with thrombectomy: a collaborative pooled analysis. Eur J Neurol 2018;25:1115–20 CrossRef Medline

33. Nahab F, Kass-Hout T, Shaltoni HM. Periprocedural antithrombotic strategies in acute ischemic stroke interventional therapy. Neurology 2012;79:5174–81 CrossRef Medline

34. Winningham MJ, Haussen DC, Nogueira RG, et al. Periprocedural heparin use in acute ischemic stroke endovascular therapy: the TREVO 2 trial. J Neurointerv Surg 2018;10:611–14 CrossRef Medline

35. Zhu F, Piotin M, Steglich-Arnholm H, et al; TITAN (Thrombectomy In TANdem Lesions) Investigators. Periprocedural heparin during endovascular treatment of tandem lesions in patients with acute ischemic stroke: a propensity score analysis from TITAN registry. Cardiovasc Intervent Radiol 2019;42:1160–67 CrossRef Medline

36. Salustio F, Motta C, Merolla S, et al. Heparin during endovascular stroke treatment seems safe. J Neurol 2019;46:733–77 CrossRef Medline

37. Anadani M, Spiotta AM, Alawieh A, et al; on behalf of the TITAN (Thrombectomy In TANdem Lesions) Investigators. Emergent carotid stenting plus thrombectomy after thrombolysis in tandem strokes: analysis of the TITAN registry. Stroke 2019;50:2250–52 CrossRef Medline

38. Zhu F, Labreuche J, Haussen DC, et al; the TITAN (Thrombectomy in Tandem Lesions) Investigators. Hemorrhagic transformation after thrombectomy for tandem occlusions: incidence, predictors, and clinical implications. Stroke 2019;50:516–19 CrossRef Medline

39. Yilmaz U, Körner H, Mühlen-Benninghaus R, et al. Acute occlusions of dual-layer carotid stents after endovascular emergency treatment of tandem lesions. Stroke 2017;48:2171–75 CrossRef Medline